A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases.

ABSTRACT:

Objectives

Inflammasomes induce maturation of the inflammatory cytokines IL-1β and IL-18, whose activity is associated with the pathophysiology of a wide range of infectious and inflammatory diseases. As validated therapeutic targets for the treatment of acute and chronic inflammatory diseases, there has been intense interest in developing small-molecule inhibitors to target inflammasome activity and reduce disease-associated inflammatory burden.

Methods

We examined the therapeutic potential of a novel small-molecule inhibitor, and associated derivatives, termed ADS032 to target and reduce inflammasome-mediated inflammation in vivo. In vitro, we characterised ADS032 function, target engagement and specificity.

Results

We describe ADS032 as the first dual

SUBMITTER: Docherty CA 

PROVIDER: S-EPMC10288073 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature